Verona Pharma plc
VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$106.40
Price+0.15%
$0.16
1Y
Price
Market Cap
$9.042b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$221.673m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$81.187m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$0.98
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$278.273m
$572.871m
Assets$294.598m
Liabilities$244.374m
DebtDebt to Assets
42.7%
-6.7x
Debt to EBITDAFree Cash Flow
-$73.026m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company